Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Blood Protein Disorders, Hematologic Diseases, Dexamethasone, Dexamethasone acetate, Pomalidomide
Brief summary
Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma
Interventions
DRUGACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
Sponsors
Celgene
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must have a documented diagnosis of multiple myeloma and have relapsed-and-refractory disease. Patients must have received at least 2 lines of prior therapies. Patients must have relapsed after having achieved at least stable disease (SD) for at least one cycle of treatment to at least one prior regimen and then developed progressive disease (PD). Patients must also have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease) * Must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen) * Must not be a candidate for autologous stem cell transplant (ASCT), has declined the option of ASCT, or has relapsed after prior ASCT * Must have measurable levels of myeloma paraprotein in serum (≥ 0.5 g/dL) or urine (≥ 0.2 g/24 hours) * Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 * Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to, and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods,and Education and Counseling Guidance must be followed per protocol * Must be able to take acetylsalicylic acid (ASA) (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended. Coumadin will be allowed provided the patient is fully anticoagulated, with an international normalized ratio (INR) of 2 to 3
Exclusion criteria
* Pregnant or lactating females * Prior therapy with HDAC inhibitor * Any of the following laboratory abnormalities: * ANC \< 1,000/µL * Platelet count \< 75,000/ µL for patients in whom \< 50% of bone marrow nucleated cells are plasma cells; and \< 50,000/ µL for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells * Hemoglobin \< 8g/dL (\<4.9 mmol/L; prior red blood cell \[RBC\] transfusion is permitted) * Creatine clearance \< 45mL/min according to Cockcroft-Gault formula. If creatine clearance calculated from the 24-hour urine sample is ≥ 45 mL/min, patient will qualify for the study * Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST), or serum glutamic pyruvic transaminase (SGPT)/ alanine aminotransferase (ALT) \> 3.0 × ULN * Serum total bilirubin \> 2.0 mg/dL * Prior history of malignancies, other than MM, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following: * Basal or squamous cell carcinoma of the skin * Carcinoma in situ of the cervix or breast * Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b) * Corrected QT interval using Fridericia's formula (QTcF) value \> 480 msec at screening; family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy; previous history of drug-induced QTc prolongation or the need for treatment with medications known or suspected of producing prolonged QTc intervals on electrocardiogram (ECG) * Positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection * Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowable * Peripheral neuropathy ≥ Grade 2 despite supportive therapy * Radiotherapy or systemic therapy (standard or an investigational or biologic anticancer agent) within 14 days of initiation of study drug treatment * Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason * Inability or unwillingness to comply with birth control requirements or regional REMS/RevAid programs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) of ACY-1215- Phase 1b | From first dose until the end of Phase 1b (up to a maximum of approximately 50 weeks). | The maximum tolerated dose (MTD) was defined as the highest dose level at which no more than 1 of 6 patients experienced a dose-limiting toxicity (DLT) within the first 28-day cycle. If no more than 1 of these 6 patients experienced a DLT within the first 28-day cycle, then the last dose level enrolled to meet these criteria was identified as the recommended dose for the Phase 2 segment of the study. |
| Overall Response Rate (ORR) Per Investigator - Phase 2 | From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months). | Overall response rate (ORR) is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: * No detectable myeloma cells in the bone marrow. * Normal free light chain ratio. * Absence of clonal cells in the bone marrow. CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * Less than 5% plasma cells in the bone marrow. VGPR: * Serum and urine M-protein detectable by immunofixation but not on electrophoresis, or * At least a 90% reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours. PR: * At least a 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours. * For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Progression (TTP) | From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months). | Time to progression (TTP) was defined as the time from the date of first dose to the date of first documentation of progressive disease (PD). PD: * Increase of 25% or more from nadir in serum M-protein, absolute increase of \>= 0.5 g/dL. * Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \>=200 mg/24 hours. * Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \>=10%. * New bone lesions or soft tissue plasmacytomas or increase size of existing bone lesions or soft tissue plasmacytomas. * Hypercalcemia attributed to myeloma. |
| Progression-free Survival (PFS) | From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months). | Progression-free survival (PFS) was defined as the time from first dose of study treatment to the first documentation of progressive disease (PD) or death from any cause during study PD: * Increase of 25% or more from nadir in serum M-protein, absolute increase of \>= 0.5 g/dL. * Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \>=200 mg/24 hours. * Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \>=10%. * New bone lesions or soft tissue plasmacytomas or increase size of existing bone lesions or soft tissue plasmacytomas. * Hypercalcemia attributed to myeloma. Calculated using Kaplan-Meier estimates. |
| Overall Response Rate (ORR) Per Central Adjudication Committee | From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months). | Overall response rate (ORR) per Central Adjudication Committee is the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: * No detectable myeloma cells in the bone marrow. * Normal free light chain ratio. * Absence of clonal cells in the bone marrow. CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * Less than 5% plasma cells in the bone marrow. VGPR: * Serum and urine M-protein detectable by immunofixation but not on electrophoresis, or * At least a 90% reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours. PR: * At least a 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours. * For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required |
| Number of Participants With Adverse Events (AEs) | From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks) | An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death. |
| Time to Response (TTR) | From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months). | Time to response (TTR) was defined as the time from first dose of study treatment to the first documentation of response (either partial response (PR) or complete response (CR)). CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * Less than 5% plasma cells in the bone marrow. PR: * At least a 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours. * For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required. |
| Number of Participants With Adverse Events (AEs) Leading to Discontinuation | From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks) | An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death. |
| Number of Participants With Adverse Events (AEs) Related to Study Drug | From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks) | An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death. |
| Plasma Levels of ACY-1215 and Pomalidomide - Phase 1b | Cycle 1 day 1, Cycle 1 Day 2, Cycle 1 Day 8 | — |
| Number of Participants With Anti-Drug Antibodies (ADA) - Phase 1b | Cycle 1 day 1, Cycle 1 Day 2, Cycle 1 Day 8 | — |
| Number of Participants With Serious Adverse Events (SAEs) | From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks) | A serious adverse event (SAE) is defined as any adverse event (AE) occurring at any dose that: * Results in death; * Is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE); * Requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay). * Results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions); * Is a congenital anomaly/birth defect; * Constitutes an important medical event. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death. |
| Duration of Response (DoR) | From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months). | Duration of Response (DOR) was defined as the time from first partial response (PR) or complete response (CR) to the first documentation of progressive disease (PD) or death. PR: * \>= 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by \>= 90% or to less than 200 mg per 24 hours. * For non-secretory myeloma, a reduction of \>= 50% in size of soft tissue plasmacytomas. CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * \< 5% plasma cells in the bone marrow. PD: * Increase of 25% or more from nadir in serum M-protein, absolute increase of \>= 0.5 g/dL. * Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \>=200 mg/24 hours. * Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \>=10%. Calculated using Kaplan-Meier estimates. |
Countries
United States
Participant flow
Pre-assignment details
The study consisted of Phase 1b (dose finding segment) part and Phase 2(dose expansion segment) part.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b - ACY-1215 Dose Level 1 Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\<=75 years) or 20 mg (\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle. | 3 |
| Phase 1b - ACY-1215 Dose Level 3 Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\<=75 years) or 20 mg (\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle. | 4 |
| Phase 2 - ACY-1215 Dose Level 1 Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\<=75 years) or 20 mg (\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle. | 85 |
| Phase 2 - ACY-1215 Dose Level 3 Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\<=75 years) or 20 mg (\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle. | 11 |
| Total | 103 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 15 | 2 |
| Overall Study | Lost to Follow-up | 0 | 0 | 1 | 0 |
| Overall Study | Other reasons | 0 | 0 | 1 | 0 |
| Overall Study | Physician Decision | 0 | 0 | 3 | 0 |
| Overall Study | Progressive disease | 3 | 4 | 57 | 8 |
| Overall Study | Withdrawal by participant | 0 | 0 | 8 | 1 |
Baseline characteristics
| Characteristic | Phase 1b - ACY-1215 Dose Level 1 | Phase 1b - ACY-1215 Dose Level 3 | Phase 2 - ACY-1215 Dose Level 1 | Phase 2 - ACY-1215 Dose Level 3 | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 2 Participants | 43 Participants | 7 Participants | 53 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 2 Participants | 42 Participants | 4 Participants | 50 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 4 Participants | 81 Participants | 11 Participants | 99 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 7 Participants | 1 Participants | 8 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 3 Participants | 4 Participants | 72 Participants | 10 Participants | 89 Participants |
| Sex: Female, Male Female | 2 Participants | 1 Participants | 40 Participants | 4 Participants | 47 Participants |
| Sex: Female, Male Male | 1 Participants | 3 Participants | 45 Participants | 7 Participants | 56 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 3 | 1 / 4 | 39 / 85 | 3 / 11 |
| other Total, other adverse events | 3 / 3 | 4 / 4 | 82 / 85 | 11 / 11 |
| serious Total, serious adverse events | 0 / 3 | 2 / 4 | 37 / 85 | 7 / 11 |
Outcome results
Primary
Maximum Tolerated Dose (MTD) of ACY-1215- Phase 1b
The maximum tolerated dose (MTD) was defined as the highest dose level at which no more than 1 of 6 patients experienced a dose-limiting toxicity (DLT) within the first 28-day cycle. If no more than 1 of these 6 patients experienced a DLT within the first 28-day cycle, then the last dose level enrolled to meet these criteria was identified as the recommended dose for the Phase 2 segment of the study.
Time frame: From first dose until the end of Phase 1b (up to a maximum of approximately 50 weeks).
Population: All treated participants in Phase 1b. Prespecified to be reported as combined for Phase 1b only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b - ACY-1215 | Maximum Tolerated Dose (MTD) of ACY-1215- Phase 1b | 320 mg/day |
Primary
Overall Response Rate (ORR) Per Investigator - Phase 2
Overall response rate (ORR) is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: * No detectable myeloma cells in the bone marrow. * Normal free light chain ratio. * Absence of clonal cells in the bone marrow. CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * Less than 5% plasma cells in the bone marrow. VGPR: * Serum and urine M-protein detectable by immunofixation but not on electrophoresis, or * At least a 90% reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours. PR: * At least a 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours. * For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required.
Time frame: From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).
Population: All treated participants in Phase 2 Efficacy evaluable population. Prespecified to be reported for Phase 2 only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b - ACY-1215 | Overall Response Rate (ORR) Per Investigator - Phase 2 | 39.0 Percent of Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Overall Response Rate (ORR) Per Investigator - Phase 2 | 71.4 Percent of Participants |
Secondary
Duration of Response (DoR)
Duration of Response (DOR) was defined as the time from first partial response (PR) or complete response (CR) to the first documentation of progressive disease (PD) or death. PR: * \>= 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by \>= 90% or to less than 200 mg per 24 hours. * For non-secretory myeloma, a reduction of \>= 50% in size of soft tissue plasmacytomas. CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * \< 5% plasma cells in the bone marrow. PD: * Increase of 25% or more from nadir in serum M-protein, absolute increase of \>= 0.5 g/dL. * Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \>=200 mg/24 hours. * Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \>=10%. Calculated using Kaplan-Meier estimates.
Time frame: From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).
Population: All treated participants in the Efficacy Evaluable population with a best response of PR or CR.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b - ACY-1215 | Duration of Response (DoR) | 20.10 Weeks |
| Phase 2 - ACY-1215 Dose Level 1 | Duration of Response (DoR) | 30.30 Weeks |
| Phase 2 - ACY-1215 Dose Level 3 | Duration of Response (DoR) | 62.75 Weeks |
Secondary
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks)
Population: All treated participants in the Safety population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) | 3 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) | 4 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) | 82 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) | 11 Participants |
Secondary
Number of Participants With Adverse Events (AEs) Leading to Discontinuation
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks)
Population: All treated participants in the Safety population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | ACY-1215 | 0 Participants |
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Dexamethasone | 0 Participants |
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Pomalidomide | 0 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | ACY-1215 | 0 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Dexamethasone | 0 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Pomalidomide | 0 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Pomalidomide | 13 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | ACY-1215 | 13 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Dexamethasone | 16 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | ACY-1215 | 1 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Dexamethasone | 1 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Leading to Discontinuation | Pomalidomide | 1 Participants |
Secondary
Number of Participants With Adverse Events (AEs) Related to Study Drug
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks)
Population: All treated participants in the Safety population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) Related to Study Drug | ACY-1215 | 1 Participants |
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Dexamethasone | 2 Participants |
| Phase 1b - ACY-1215 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Pomalidomide | 3 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Related to Study Drug | ACY-1215 | 4 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Dexamethasone | 3 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Pomalidomide | 4 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Pomalidomide | 62 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) Related to Study Drug | ACY-1215 | 63 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Dexamethasone | 57 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Related to Study Drug | ACY-1215 | 9 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Dexamethasone | 9 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Adverse Events (AEs) Related to Study Drug | Pomalidomide | 11 Participants |
Secondary
Number of Participants With Anti-Drug Antibodies (ADA) - Phase 1b
Time frame: Cycle 1 day 1, Cycle 1 Day 2, Cycle 1 Day 8
Population: All treated participants with available ADA results. Prespecified to be reported for Phase 1b only. Data not collected.
| Arm | Measure | Group | Value |
|---|---|---|---|
| Unknown | Number of Participants With Anti-Drug Antibodies (ADA) - Phase 1b | ACY-1215 | — |
| Unknown | Number of Participants With Anti-Drug Antibodies (ADA) - Phase 1b | Pomalidomide | — |
Secondary
Number of Participants With Serious Adverse Events (SAEs)
A serious adverse event (SAE) is defined as any adverse event (AE) occurring at any dose that: * Results in death; * Is life-threatening (ie, in the opinion of the Investigator, the participant is at immediate risk of death from the AE); * Requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay). * Results in persistent or significant disability/incapacity (a substantial disruption of the participant's ability to conduct normal life functions); * Is a congenital anomaly/birth defect; * Constitutes an important medical event. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks)
Population: All treated participants in the Safety population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b - ACY-1215 | Number of Participants With Serious Adverse Events (SAEs) | 0 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Serious Adverse Events (SAEs) | 2 Participants |
| Phase 2 - ACY-1215 Dose Level 1 | Number of Participants With Serious Adverse Events (SAEs) | 37 Participants |
| Phase 2 - ACY-1215 Dose Level 3 | Number of Participants With Serious Adverse Events (SAEs) | 7 Participants |
Secondary
Overall Response Rate (ORR) Per Central Adjudication Committee
Overall response rate (ORR) per Central Adjudication Committee is the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: * No detectable myeloma cells in the bone marrow. * Normal free light chain ratio. * Absence of clonal cells in the bone marrow. CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * Less than 5% plasma cells in the bone marrow. VGPR: * Serum and urine M-protein detectable by immunofixation but not on electrophoresis, or * At least a 90% reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours. PR: * At least a 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours. * For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required
Time frame: From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).
Population: All treated participants in the Efficacy Evaluable population. Data not collected.
Secondary
Plasma Levels of ACY-1215 and Pomalidomide - Phase 1b
Time frame: Cycle 1 day 1, Cycle 1 Day 2, Cycle 1 Day 8
Population: All treated participants with available PK results. Prespecified to be reported for Phase 1b only. Data not collected.
| Arm | Measure | Group | Value |
|---|---|---|---|
| Unknown | Plasma Levels of ACY-1215 and Pomalidomide - Phase 1b | ACY-1215 | — |
| Unknown | Plasma Levels of ACY-1215 and Pomalidomide - Phase 1b | Pomalidomide | — |
Secondary
Progression-free Survival (PFS)
Progression-free survival (PFS) was defined as the time from first dose of study treatment to the first documentation of progressive disease (PD) or death from any cause during study PD: * Increase of 25% or more from nadir in serum M-protein, absolute increase of \>= 0.5 g/dL. * Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \>=200 mg/24 hours. * Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \>=10%. * New bone lesions or soft tissue plasmacytomas or increase size of existing bone lesions or soft tissue plasmacytomas. * Hypercalcemia attributed to myeloma. Calculated using Kaplan-Meier estimates.
Time frame: From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).
Population: All treated participants in the Efficacy Evaluable population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b - ACY-1215 | Progression-free Survival (PFS) | 10.30 Weeks |
| Phase 2 - ACY-1215 Dose Level 3 | Progression-free Survival (PFS) | 6.30 Weeks |
| Phase 2 - ACY-1215 Dose Level 1 | Progression-free Survival (PFS) | 20.00 Weeks |
| Phase 2 - ACY-1215 Dose Level 3 | Progression-free Survival (PFS) | 62.70 Weeks |
Secondary
Time to Progression (TTP)
Time to progression (TTP) was defined as the time from the date of first dose to the date of first documentation of progressive disease (PD). PD: * Increase of 25% or more from nadir in serum M-protein, absolute increase of \>= 0.5 g/dL. * Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \>=200 mg/24 hours. * Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \>=10%. * New bone lesions or soft tissue plasmacytomas or increase size of existing bone lesions or soft tissue plasmacytomas. * Hypercalcemia attributed to myeloma.
Time frame: From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).
Population: All treated participants in the Efficacy Evaluable population who had PD.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Phase 1b - ACY-1215 | Time to Progression (TTP) | 22.43 Weeks |
| Phase 2 - ACY-1215 Dose Level 3 | Time to Progression (TTP) | 6.20 Weeks |
| Phase 2 - ACY-1215 Dose Level 1 | Time to Progression (TTP) | 29.82 Weeks |
| Phase 2 - ACY-1215 Dose Level 3 | Time to Progression (TTP) | 83.22 Weeks |
Secondary
Time to Response (TTR)
Time to response (TTR) was defined as the time from first dose of study treatment to the first documentation of response (either partial response (PR) or complete response (CR)). CR: * Negative immunofixation on the serum and urine. * Disappearance of any soft tissue plasmacytomas. * Less than 5% plasma cells in the bone marrow. PR: * At least a 50% reduction in serum M-protein. * Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours. * For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required.
Time frame: From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).
Population: All treated participants in the Efficacy Evaluable population with a best response of PR or CR.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Phase 1b - ACY-1215 | Time to Response (TTR) | 8.50 Weeks |
| Phase 2 - ACY-1215 Dose Level 1 | Time to Response (TTR) | 10.83 Weeks |
| Phase 2 - ACY-1215 Dose Level 3 | Time to Response (TTR) | 12.96 Weeks |